Facilitating T1 Translational Aging Research: Preclinical and Early Phase Human Studies (UG3/UH3 Clinical Trial Optional)
ID: 356873Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356873

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-027.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the Facilitating T1 Translational Aging Research funding opportunity, aimed at advancing new therapeutics for aging-related conditions through preclinical and early-phase human studies. This initiative focuses on two main project categories: traditional drug development and data-driven computational drug repurposing strategies, with the UG3 phase supporting planning and preliminary studies for up to two years, followed by the UH3 phase for implementation activities lasting up to three years. The funding opportunity is significant for improving health outcomes for older adults, with a total anticipated funding of $2.5 million available for up to five awards, and applications are due by January 10, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AG-25-027-Full-Announcement.html
    RFA-AG-25-027.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is inviting applications for funding to support T1 translational aging research, aimed at advancing new therapeutics for aging-related conditions. This opportunity focuses on two project categories: traditional drug development and data-driven computational drug repurposing strategies. The UG3 phase will fund planning and preliminary studies for up to two years, followed by the UH3 phase, which can last up to three years for implementation activities. While this initiative encourages innovation by integrating computational approaches into drug development, it excludes applications concerning neurodegenerative diseases and Alzheimer’s-related conditions. A total of $2.5 million is anticipated for up to five awards, with specific budget caps for each phase. Eligible applicants include educational institutions, non-profit organizations, and government agencies. Applications must comply with stringent guidelines, including specified milestones and timelines, and will undergo rigorous peer review before potential funding decisions. This funding opportunity reflects a commitment to improving health outcomes for older adults through novel therapeutic approaches in aging research.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for Facilitating Preclinical and Early Phase Human Studies for New Therapeutics (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for facilitating preclinical and early phase human studies for new therapeutics, specifically targeting aging-related conditions. This initiative aims to advance T1 translational aging research, focusing on therapeutics that progress from preclinical stages to first-in-human trials, addressing conditions such as sarcopenia and heart failure with preserved ejection fraction (HFpEF). The funding opportunity, categorized under health-related activities, will utilize the UG3/UH3 Cooperative Agreement mechanism, with an estimated total program funding of $2.5 million. Interested applicants should prepare to submit their applications by fall 2024, with the NOFO expected to be published in summer 2024 and awards anticipated by July 2025.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Research Infrastructure Development for Interdisciplinary Aging Studies (R61/R33 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research Infrastructure Development for Interdisciplinary Aging Studies (R61/R33 - Clinical Trial Optional)" aimed at advancing the science of aging through innovative research infrastructure. This initiative invites applications from a diverse range of eligible institutions to develop sustainable frameworks that address critical interdisciplinary questions in aging, with a focus on areas such as machine learning applications, health disparities, and behavioral aspects of aging. The funding mechanism provides up to five years of support, including two years for initial developmental activities and up to three years for expanded activities, with an award ceiling of $500,000. Interested applicants can find more information and application guidelines at the NIH website, and must submit their proposals by December 2, 2025, to be considered for this discretionary grant opportunity.
    Complex Integrated Multi-Component Projects in Aging Research (U19 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for Complex Integrated Multi-Component Projects in Aging Research, designated as a U19 Clinical Trial Optional grant. This initiative aims to support large-scale, multidisciplinary research projects that address common questions related to aging, encouraging collaboration among investigators from various institutions. The program is particularly significant as it seeks to advance scientific knowledge in aging while addressing health disparities and promoting innovative research approaches. Interested applicants, including higher education institutions, nonprofits, and government agencies, can submit proposals until September 25, 2025, with a maximum project period of five years. For further inquiries, applicants may contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-22-213.html.
    Research Infrastructure Development for Interdisciplinary Aging Studies (R61/R33 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research Infrastructure Development for Interdisciplinary Aging Studies" (R61/R33 - Clinical Trial Optional) aimed at advancing interdisciplinary research in aging. This initiative encourages applicants to develop novel research infrastructure that addresses critical questions in aging through collaborative efforts across various disciplines, including biological aging and behavioral science. The funding is structured in two phases, providing up to $500,000 annually for initial activities over two years (R61) followed by three years for expanded activities (R33), with applications accepted from eligible institutions and organizations until December 3, 2025. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-218.html.
    Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies (R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity (PAR-23-054) aimed at advancing interdisciplinary research in aging through the development and utilization of novel research infrastructures. This initiative encourages applicants to propose projects that enhance the understanding of aging by fostering collaborations across various scientific disciplines, with a focus on producing tangible scientific results such as new knowledge or tools. The funding is particularly relevant for addressing significant aging-related questions and improving the management of age-related health issues. Eligible applicants include higher education institutions, nonprofits, and government entities, with a funding ceiling of $500,000 and a close date for applications set for December 2, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-054.html.
    Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Seamless Early-Stage Clinical Drug Development program, aimed at accelerating the clinical evaluation of novel treatments for Alzheimer’s Disease (AD) and related dementias (ADRD). This funding opportunity utilizes the UG3/UH3 phased award mechanism to streamline the assessment of pharmacological interventions that engage non-amyloid/non-tau mechanisms, requiring applicants to bundle independent protocols for Phase 1 and Phase 1b/Phase 2a clinical trials while achieving specified safety and tolerability milestones. This initiative is critical in addressing the growing human and economic burdens posed by AD and ADRD, reflecting a commitment to innovative treatment development. Interested applicants must adhere to submission guidelines, with the earliest application deadline set for January 19, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for multidisciplinary research on HIV/AIDS and aging through the R21 Exploratory/Developmental Research Grant program. This initiative invites applications that aim to enhance the understanding of the biological, clinical, and socio-behavioral aspects of aging in the context of HIV infection, with specific objectives to improve prevention, testing, treatment strategies, and management of HIV-related health issues in diverse populations, particularly older adults aged 70 and above. The grant provides funding of up to $275,000 for a two-year period, with key submission dates starting April 4, 2024, and a closing date for applications set for January 7, 2027. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies (R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies," aimed at enhancing research infrastructure to support interdisciplinary projects in aging science. This funding opportunity encourages the development of novel research partnerships and seeks applications that demonstrate significant advancements in research infrastructure, with a focus on biomedical, social, and behavioral research related to aging mechanisms. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and government entities, with a funding cap of $500,000 per year for projects lasting up to five years. Interested parties can find more information and submit applications through Grants.gov, with a submission deadline of December 2, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel Therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD)." This initiative aims to streamline the early-stage evaluation of promising pharmacological interventions by bundling independent protocols for phase 1 clinical trials with phase 1b/phase 2a trials, focusing on non-amyloid/non-tau mechanisms that address cognitive and neuropsychiatric symptoms across various stages of the disease. The program is particularly significant given the rising prevalence of Alzheimer's and the associated economic burden, emphasizing the need for innovative treatments as the aging population grows. Eligible applicants include a diverse range of organizations, such as higher education institutions and community-based organizations, with proposals due by November 19, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-226.html.